Education
About Us
Working with TipRanks
Follow Us
Alto Neuroscience, Inc. (ANRO)
NYSE:ANRO
ANRO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.60 - $15.04
Previous CloseN/A
Volume104.17K
Average Volume (3M)2.20M
Market Cap
$177.08M
Enterprise Value-$60.72M
Total Cash (Recent Filing)$147.59M
Total Debt (Recent Filing)$4.21M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Nov 18, 2025EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding27,076,630
10 Day Avg. Volume6,443,259
30 Day Avg. Volume2,204,538
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.34
Enterprise Value/Revenue-154.11
Enterprise Value/Gross Profit221.60
Enterprise Value/Ebitda0.95
Forecast
1Y Price Target
$12.67Price Target Upside113.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Financial StabilityManagement reiterated that it expects its current cash position to fund operations into 2028 and through at least four key clinical readouts.
Pipeline DevelopmentAlto Neuroscience's asset ALTO-101 is eligible for Accelerated Approval and Priority Review, enhancing its potential for a quicker approval process.
Regulatory AdvancementsALTO-101 received Fast Track Designation by the FDA, highlighting the unmet need and opportunity in cognitive impairment associated with schizophrenia.
Bears Say
Market CompetitionThe market acceptance and experience of esketamine, marketed as SPRAVATO by Johnson & Johnson, highlights potential for ANRO's offerings in treatment-resistant depression and major depressive disorder.
Regulatory ChallengesBiomarkers must be quick, readily analyzable, easily integrated into existing workflows, and reimbursed, which both cognitive tests and EEG-based biomarkers could achieve.
Alto Neuroscience, Inc. News
ANRO FAQ
What was Alto Neuroscience, Inc.’s price range in the past 12 months?
Alto Neuroscience, Inc. lowest stock price was $1.60 and its highest was $15.04 in the past 12 months.
What is Alto Neuroscience, Inc.’s market cap?
Alto Neuroscience, Inc.’s market cap is $177.08M.
When is Alto Neuroscience, Inc.’s upcoming earnings report date?
Alto Neuroscience, Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 40 days.
How were Alto Neuroscience, Inc.’s earnings last quarter?
Alto Neuroscience, Inc. released its earnings results on Aug 13, 2025. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.599 by -$0.051.
Is Alto Neuroscience, Inc. overvalued?
According to Wall Street analysts Alto Neuroscience, Inc.’s price is currently Undervalued.
Does Alto Neuroscience, Inc. pay dividends?
Alto Neuroscience, Inc. does not currently pay dividends.
What is Alto Neuroscience, Inc.’s EPS estimate?
Alto Neuroscience, Inc.’s EPS estimate is -0.69.
How many shares outstanding does Alto Neuroscience, Inc. have?
Alto Neuroscience, Inc. has 27,076,630 shares outstanding.
What happened to Alto Neuroscience, Inc.’s price movement after its last earnings report?
Alto Neuroscience, Inc. reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.599. Following the earnings report the stock price went down -0.319%.
Which hedge fund is a major shareholder of Alto Neuroscience, Inc.?
Currently, no hedge funds are holding shares in ANRO
Alto Neuroscience, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.67 (113.30% Upside)
$12.67 (113.30% Upside)
Hedge Fund Trend
Decreased
By 400.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.8%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-46.19%
12-Months-Change
Fundamentals
Return on Equity
-42.78%
Trailing 12-Months
Asset Growth
-20.01%
Trailing 12-Months
Company Description
Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.
ANRO Stock 12 Month Forecast
Average Price Target
$12.67
▲(113.30% Upside)
Technical Analysis
Cassava Sciences
―
Corbus Pharmaceuticals
―
Forte Biosciences
―
Milestone Pharmaceuticals
―
Elicio Therapeutics
―
Ownership Overview
8.38% Insiders
9.33% Mutual Funds
34.62% Other Institutional Investors
43.62% Public Companies and
Individual Investors